Societal CDMO, Inc. announced that it has been selected by Xequel Bio, Inc. to provide CDMO services to support the ongoing clinical development of a patented new chemical entity based on its aCT1 (alpha-Connexin carboxyl-Terminal 1 peptide) platform. The agreement spans a range of Societal CDMO's offerings including process development and clinical trial services, culminating in cGMP manufacturing of the compound and placebo for upcoming Phase 2 clinical trials of iNexin(TM) (aCT1 ophthalmic solution). iNexin is a sterile, preservative-free ophthalmic solution containing aCT1 peptide that is currently being evaluated by Xequel for the potential treatment of persistent corneal epithelial defects (PCED).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.1 USD | +0.92% | -.--% | +213.84% |
Apr. 08 | Societal CDMO, Inc. Announces Board and Committee Resignations | CI |
Apr. 08 | Societal CDMO, Inc.(NasdaqCM:SCTL) dropped from NASDAQ Composite Index | CI |
1st Jan change | Capi. | |
---|---|---|
+213.84% | 116M | |
+32.36% | 694B | |
+29.69% | 593B | |
-1.60% | 371B | |
+20.07% | 331B | |
+6.04% | 290B | |
+14.43% | 239B | |
-3.52% | 209B | |
+10.13% | 209B | |
+9.27% | 169B |
- Stock Market
- Equities
- SCTL Stock
- News Societal CDMO, Inc.
- Xequel Bio, Inc. Selects Societal CDMO Services to Support Ongoing Clinical Development of iNexin